BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28036271)

  • 1. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients.
    Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F
    Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.
    Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W
    Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
    Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer.
    Chen HT; Zheng JM; Zhang YZ; Yang M; Wang YL; Man XH; Chen Y; Cai QC; Li ZS
    Pancreas; 2017 Mar; 46(3):323-334. PubMed ID: 28099248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
    Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
    PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis.
    Xu TP; Shen H; Liu LX; Shu YQ
    Cancer Epidemiol; 2013 Oct; 37(5):725-31. PubMed ID: 23763828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
    Li S; Shen Y; Wang M; Yang J; Lv M; Li P; Chen Z; Yang J
    Oncotarget; 2017 May; 8(19):32043-32054. PubMed ID: 28410191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
    Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
    Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
    Kim SH; Das K; Noreen S; Coffman F; Hameed M
    World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis.
    Lin SC; Gan ZH; Yao Y; Min da L
    PLoS One; 2015; 10(8):e0136374. PubMed ID: 26305693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
    Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
    PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis.
    Liu J; Guo H; Mao K; Zhang K; Deng H; Liu Q
    Breast Cancer Res Treat; 2016 Feb; 156(1):149-62. PubMed ID: 26902609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
    Chen Y; Jiang L; Gao B; Cheng ZY; Jin J; Yang KH
    Breast Cancer Res Treat; 2016 Jun; 157(3):517-25. PubMed ID: 27246814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies.
    Bian B; Li L; Yang J; Liu Y; Xie G; Zheng Y; Zeng L; Zeng J; Shen L
    Cancer Cell Int; 2019; 19():259. PubMed ID: 31624472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: A meta-analysis.
    Fan YH; Fang H; Ji CX; Xie H; Xiao B; Zhu XG
    Clin Chim Acta; 2017 Mar; 466():120-126. PubMed ID: 28089750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
    Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
    Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.